Valuation SCYNEXIS, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-07 EDT			5-day change	1st Jan Change
4.780 ^USD	-1.24%		+2.58%	-5.52%

10-06	SCYNEXIS, Inc. Announces Completion Of Phase 1 Study Of SCY-770 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease	CI
09-28	SCYNEXIS, Inc. Receives Biomedical Advanced Research And Development Authority Contract Providing Up To $214 Million In Non-Dilutive Funding For The Development Of SCY-247	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	174	50.94	82.97	45.92	26.54	48.16	-	-
Change	-	-70.72%	62.87%	-44.66%	-42.2%	81.46%	-	-
Enterprise Value (EV)	174	50.94	82.97	45.92	26.54	48.16	48.16	48.16
Change	-	-70.72%	62.87%	-44.66%	-42.2%	81.46%	0%	0%
P/E	-4.88x	-1.06x	1.6x	-2.75x	-3.72x	-1.66x	-2.09x	-2.92x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0.1x	-0x	0x	0.1x	-0x	0.1x	0.1x
Capitalization / Revenue	13.2x	10x	0.59x	12.3x	1.29x	77.7x	7.21x	3.42x
EV / Revenue	0x	0x	0x	0x	0x	77.7x	7.21x	3.42x
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	0x	-0x	-0x	-1.19x	-1.94x	-2.1x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-10	-11.76	11.12	-3.52	-1.36	-2.91	-2.315	-1.66
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	13.16	5.091	140.1	3.746	20.6	0.6195	6.677	14.08
EBITDA	-	-85.15	-	-	-	-	-	-
EBIT ¹	-60.84	-85.76	72.67	-37.12	-16.07	-40.32	-24.83	-22.96
Net income ¹	-32.87	-62.81	67.04	-21.29	-8.609	-30.55	-32.43	-22.46
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	48.800	12.480	17.840	9.680	5.059	4.840	4.840	4.840
Nbr of stocks (in thousands)	3,565	4,082	4,651	4,744	5,246	9,950	-	-
Announcement Date	3/29/22	3/31/23	3/28/24	3/12/25	3/4/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
SCYNEXIS, INC.	-1.66x	-	-	-	48.16M
ELI LILLY AND COMPANY	32.87x	11.93x	24.1x	0.6%	1,032B
JOHNSON & JOHNSON	28.34x	6.29x	17.98x	2.1%	614B
ABBVIE INC.	37.73x	7.89x	16.32x	2.6%	471B
MERCK & CO., INC.	103.26x	5.79x	24.59x	2.4%	350B
ROCHE HOLDING AG	19.01x	4.63x	11.48x	2.86%	337B
NOVARTIS AG	19.87x	5.19x	12.84x	3.07%	268B
ASTRAZENECA PLC	20.52x	4.22x	12.02x	2.1%	246B
AMGEN INC.	25.43x	6.65x	11.85x	2.51%	218B
GILEAD SCIENCES, INC.	-43.62x	6.37x	24.89x	2.28%	179B
Average	24.17x	6.55x	17.34x	2.28%	371.49B
Weighted average by Cap.	32.24x	7.67x	18.71x	1.95%